# A Study to Determine Whether EGFR Status by FISH Can Predict Results in Non Small Cell Lung Cancer (NSCLC) Patients Treated With Cetuximab, Carboplatin and Paclitaxel

> **NCT00768131** · PHASE2 · WITHDRAWN · sponsor: **Eli Lilly and Company**

## Conditions studied

- Lung Neoplasms
- Carcinoma, Non-Small-Cell Lung

## Interventions

- **DRUG:** Cetuximab
- **DRUG:** Paclitaxel
- **DRUG:** Carboplatin

## Key facts

- **NCT ID:** NCT00768131
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2008-10
- **Primary completion:** 2008-10
- **Final completion:** 2008-10
- **Target enrollment:** 0 (ACTUAL)
- **Last updated:** 2015-10-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00768131

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00768131, "A Study to Determine Whether EGFR Status by FISH Can Predict Results in Non Small Cell Lung Cancer (NSCLC) Patients Treated With Cetuximab, Carboplatin and Paclitaxel". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00768131. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*